Sonde Health raised $19.25 million in Series B funding to globalize its voice-based disease screening technology with partners in Korea and India, CEO David Liu tells Axios exclusively.
Why it matters: Noninvasive health tracking gained significant traction during to the pandemic, and vocal markers have long loomed as a lucrative potential arena for further exploration.
